Latest On Oxford Biomedica plc (OXBDF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-27 01:48 EST | News | Oxford Biomedica plc reports FY results | N/A |  |
| 2023-04-26 01:39 EST | News | Oxford Biomedica plc (OXBDF) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-09-16 04:01 EST | News | Oxford Biomedica plc (OXBDF) Q2 2022 Earnings Call Transcript | N/A | |
| 2022-09-15 09:51 EST | News | Oxford Biomedica plc GAAP EPS of 0.00p, revenue of £64.03M | N/A | |
| 2022-07-01 17:07 EST | News | AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot | N/A | |
| 2022-04-20 23:35 EST | News | Oxford Biomedica reports 63% revenue growth linked to AstraZeneca vaccine supply: Prelim | N/A | |
| 2022-04-20 23:35 EST | News | Oxford Biomedica Plc (OXBDF) Interim CEO Dr. Roch Doliveux on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-12 00:21 EST | News | Oxford Biomedica completes deal with Homology Medicines to set up 1st US subsidiary | N/A | |
| 2022-02-01 03:32 EST | News | Sio Gene announces resignation of CEO; ends licensing deal with Oxford Biomedica | N/A | |
| 2022-01-28 18:44 EST | News | Oxford Biomedica inks deal with Homology Medicines to expand viral vector offerings | N/A | |
| 2022-01-24 15:18 EST | News | Oxford Biomedica in pact with Virica Biotech to improve production of gene therapies | N/A | |
| 2021-09-22 17:37 EST | News | Oxford Biomedica plc reports 1H results | N/A | |
| 2021-09-22 17:36 EST | News | Oxford Biomedica shares rally on robust 1H results; positive second half outlook | N/A | |
| 2021-09-22 17:36 EST | News | Oxford Biomedica plc 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-09-22 17:36 EST | News | Oxford Biomedica Plc's (OXBDF) CEO John Dawson On Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-04-16 07:21 EST | News | Oxford Biomedica plc (OXBDF) CEO John Dawson on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-04-16 07:21 EST | News | Oxford Biomedica plc 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-04-15 13:28 EST | News | Oxford Biomedica reported FY prelim revenue growth of 37% | N/A | |
| 2020-12-04 18:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 19:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-22 12:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-21 11:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 17:07 EST | News | Oxford BioMedica reports 1H results | N/A | |
| 2020-09-17 17:07 EST | News | Oxford Biomedica plc 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-09-17 17:06 EST | News | Oxford Biomedica inks R&D pact with Papyrus Therapeutics for gene therapy for cancer | N/A | |
| 2020-09-17 17:06 EST | News | Oxford Biomedica plc (OXBDF) CEO John Dawson on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-09-17 08:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-02 04:30 EST | News | Oxford Biomedica inks COVID-19 vaccine supply deal with AstraZeneca | N/A | |
| 2020-08-14 12:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 04:37 EST | News | Oxford Biomedica signs DMLA with Beam Therapeutics for LentiVector platform for next generation CAR-T therapeutics | N/A | |
| 2020-07-31 14:51 EST | News | Axovant signs gene therapy supply deal with Oxford Biomedica | N/A | |
| 2020-07-31 11:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-22 11:28 EST | News | SanSino COVID-19 vaccine candidate shows robust action in early-stage study | N/A | |
| 2020-07-22 11:28 EST | News | AstraZeneca/Oxford COVID-19 vaccine rollout not a given this year | N/A | |
| 2020-07-22 11:28 EST | News | AstraZeneca/Oxford COVID-19 vaccine shows positive effect in early-stage study | N/A | |
| 2020-07-21 07:31 EST | News | AstraZeneca/Oxford COVID-19 vaccine candidate shows robust action in early-stage study | N/A | |
| 2020-07-16 06:27 EST | News | AstraZeneca jumps 7% ahead of COVID-19 vaccine update | N/A | |
About Oxford Biomedica plc (OXBDF):
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
General
- Name Oxford Biomedica plc
- Symbol OXBDF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 584
- Last Split Factor1:50
- Last Split Date2018-05-30
- Fiscal Year EndDecember
- Web URLhttp://www.oxb.com
Valuation
- Forward PE 117.65
- Price/Sales (Trailing 12 Mt.) 11.88
- Price/Book (Most Recent Quarter) 7.72
- Enterprise Value Revenue 17.19
- Enterprise Value EBITDA 789.08
Financials
- Most Recent Quarter 2020-06-30
- Profit Margin -19%
- Return on Assets -6%
- Return on Equity -13%
- Earnings Per Share -$0.01
- Revenue Per Share $0
- Gross Profit 28.34 million
- Quarterly Earnings Growth 5.9%
Highlights
- Market Capitalization 1.21 billion
- Book Value Per Share $0.64
Share Statistics
- Shares Outstanding 82.38 million
- Shares Float 60.84 million
- % Held by Insiders 1641%
- % Held by Institutions 72.45%
Technicals
- Beta 0.62
- 52 Week High $14.6
- 52 Week Low $6
- 50 Day Moving Average 13.92
- 200 Day Moving Average 13.7
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Oxford Biomedica plc (OXBDF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Oxford Biomedica plc (OXBDF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-06-30 | $N/A | -$0.05 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $N/A | -$0.05 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $N/A | -$0.05 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $16.05 million | -$0.05 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $16.05 million | -$0.09 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $15.75 million | -$0.10 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $15.75 million | $0.02 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $17.64 million | $0.02 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $17.64 million | $0.05 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $10.95 million | $0.05 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $10.95 million | -$0.06 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $6.05 million | -$0.06 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $5.89 million | -$0.04 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $7.65 million | -$0.03 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $7.65 million | -$0.08 | $0.00 | |
| 2016-06-30 | 2016-09-30 | -$0.08 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.12 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.13 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.10 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.10 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.09 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.09 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.06 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.06 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.14 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.13 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.15 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.15 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.16 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.16 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.11 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.11 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.21 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.21 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.18 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.19 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.35 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.35 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.53 | $0.00 |
Oxford Biomedica plc (OXBDF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 8.81 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -6.06 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 2.01 million |
| Gross Profit | N/A | N/A | N/A | N/A | 10.2 million |
| Ebit | N/A | N/A | N/A | N/A | -2.45 million |
| Operating Income | N/A | N/A | N/A | N/A | -2.45 million |
| Income Tax Expense | 276500 | 276500 | -1.44 million | -1.44 million | -972500 |
| Total Revenue | N/A | N/A | N/A | N/A | 16.05 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 5.85 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -3.61 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -5.08 million |
| Net Income Applicable to Common Shares | -3.34 million | -3.34 million | -2.95 million | -2.95 million | -5.08 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | 74000 |
| Change to Liabilities | 702000 | 702000 | -2.8 million | -2.8 million | 3.18 million |
| Total Cash Flow from Investing Activities | -1.41 million | -1.41 million | -2.33 million | -2.33 million | -7.36 million |
| Net Borrowings | -253000 | -253000 | -182000 | -182000 | -22.03 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | 3.63 million |
| Change to Operating Activities | 307500 | 307500 | 25000 | 25000 | 4000 |
| Change in Cash | N/A | N/A | N/A | N/A | -3.09 million |
| Total Cash from Operating Activities | -469000 | -469000 | -2.41 million | -2.41 million | 652500 |
| Depreciation | N/A | N/A | N/A | N/A | 1.4 million |
| Other Cash Flow from Investing Activities | 6500 | 6500 | 27500 | 27500 | 24500 |
| Change to Inventory | N/A | N/A | N/A | N/A | 567000 |
| Change to Account Receivables | N/A | N/A | N/A | N/A | -2.58 million |
| Other Cash Flow from Financing Activities | -766500 | -766500 | -78000 | -78000 | -2 million |
| Change to Net Income | 1.44 million | 1.44 million | 1.26 million | 1.26 million | 3.17 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | 7.46 million |
Balance Sheet:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 51.35 million | N/A | 47.3 million | N/A | 48.88 million |
| Total Stockholder Equity | 108.84 million | N/A | 75.63 million | N/A | 80.2 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | 22.33 million |
| Total Assets | 160.19 million | N/A | 122.93 million | N/A | 129.08 million |
| Common Stock | N/A | N/A | 38.42 million | 38.42 million | 38.37 million |
| Other Current Assets | N/A | 40.97 million | N/A | N/A | 9.56 million |
| Retained Earnings | -193.12 million | -193.12 million | -187.7 million | -187.7 million | -183.08 million |
| Other Liabilities | N/A | 10.3 million | 10.45 million | 10.45 million | 6.71 million |
| Other Assets | N/A | 3.61 million | 3.96 million | 3.96 million | 3.6 million |
| Cash | 50.62 million | N/A | 16.24 million | N/A | 26.07 million |
| Total Current Liabilities | 31.26 million | N/A | 28.94 million | N/A | 34.01 million |
| Other Stockholder Equity | N/A | 2.29 million | 2.29 million | 2.29 million | 2.29 million |
| Property, Plant & Equipment | N/A | 66.09 million | 61.93 million | 61.93 million | 50.29 million |
| Total Current Assets | 90.41 million | N/A | 56.94 million | N/A | 75.09 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | N/A | 108.76 million | 75.54 million | 75.54 million | 80.1 million |
| Short Term Investments | N/A | N/A | 2.72 million | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 3.17 million | N/A | 2.58 million | N/A | 3.12 million |
| Accounts Payable | 5.84 million | N/A | 7.31 million | N/A | 5.26 million |
Oxford Biomedica plc (OXBDF) Chart:
Oxford Biomedica plc (OXBDF) News:
Below you will find a list of latest news for Oxford Biomedica plc (OXBDF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Oxford Biomedica plc (OXBDF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Oxford Biomedica plc (OXBDF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|